Right Ventricular versus Biventricular Antitachycardia Pacing in the Termination of Ventricular Tachyarrhythmia in Patients Receiving Cardiac Resynchronization Therapy: The ADVANCE CRT-D Trial

Background: The purpose of this investigation is to compare the efficacy of antitachycardia pacing (ATP) delivered via the right ventricular (RV) lead versus ATP delivered simultaneously via the right and left ventricular leads (biventricular [BiV]) in the termination of ventricular tachyarrhythmia...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cardiovascular electrophysiology 2006-05, Vol.17 (5), p.504-507
Main Authors: SCHWAB, JOERG O., GASPARINI, MAURIZIO, ANSELME, FRÉDÉRIC, MABO, PHILIPPE, PEINADO, RAFAEL, LAVERGNE, THOMAS, BOCCHIARDO, MARIO, MASCIOLI, GIOSUÈ, PASSARDI, MICAELA, MAINARDIS, MARC
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
antitachycardia pacing
biventricular pacing
Cardiac Pacing, Artificial - statistics & numerical data
cardiac resynchronization therapy
Combined Modality Therapy - statistics & numerical data
Europe - epidemiology
Female
Humans
implantable cardioverter/defibrillator
Male
Middle Aged
Prospective Studies
Randomized Controlled Trials as Topic
Risk Assessment - methods
Risk Factors
Tachycardia, Ventricular - epidemiology
Tachycardia, Ventricular - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: The purpose of this investigation is to compare the efficacy of antitachycardia pacing (ATP) delivered via the right ventricular (RV) lead versus ATP delivered simultaneously via the right and left ventricular leads (biventricular [BiV]) in the termination of ventricular tachyarrhythmia (VT) in patients receiving cardiac resynchronization therapy (CRT) with ICD capabilities. Methods and Results: The ADVANCE CRT is a prospective, multicenter, randomized, parallel trial evaluating RV versus BiV ATP in the termination of VT in CRT patients. The study will test the hypothesis that BiV ATP is superior to RV ATP in the termination of VT and fast VT. All patients with class I and IIa indications for an ICD implantation and CRT are included. The sample size has been estimated to 400 participants followed for 12 months to show a 10% benefit of BiV versus RV ATP. The efficacy of BiV ATP to terminate all VT presents the primary endpoint. The investigation is expected to be completed in 2007. Conclusions: The ADVANCE CRT trial is the first large randomized clinical investigation evaluating the efficacy of BiV ATP in patients under CRT and ICD therapy.
ISSN:1045-3873
1540-8167
DOI:10.1111/j.1540-8167.2006.00433.x